<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The pharmacological properties of a novel <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi>/<z:chebi fb="11" ids="26333">prostaglandin</z:chebi> endoperoxide receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, ONO-3708, on blood vessels were examined in vitro and in vivo </plain></SENT>
<SENT sid="1" pm="."><plain>ONO-3708, 10 microM, inhibited the rabbit aorta contractions induced by <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi>, <z:chebi fb="0" ids="15554">prostaglandin H2</z:chebi>, 11,9-epoxymethano-<z:chebi fb="0" ids="15554">prostaglandin H2</z:chebi> (U-46619) or <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> F2 alpha without affecting the contractions induced by <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi>, <z:chebi fb="19" ids="28790">serotonin</z:chebi> or <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>ONO-3708, at a concentration of 1 to 100 nM, appeared to be a competitive inhibitor of the contractile responses of the canine basilar artery to 9,11-epithio-11,12-methano-<z:chebi fb="0" ids="15627">thromboxane A2</z:chebi> (STA2), U-46619 and PGF2 alpha, and a non-competitive inhibitor of the contractile responses to 15-<z:chebi fb="0" ids="29792">hydroperoxy</z:chebi>-eicosatetraenoic acid (15-<z:chebi fb="0" ids="24644">HPETE</z:chebi>) </plain></SENT>
<SENT sid="3" pm="."><plain>In in vivo studies, ONO-3708 (10 and 100 micrograms/kg per min i.v.) ameliorated the decrease in diameter of the basilar artery induced by the i.v. infusion of STA2 (0.1 microgram/kg per min) in cats </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, infusion of ONO-3708 (10 and 30 micrograms/kg per min i.v.) prevented the <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> in an experimental <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> model in dogs </plain></SENT>
<SENT sid="5" pm="."><plain>These results indicate that ONO-3708 is a potent <z:chebi fb="68" ids="48706">antagonist</z:chebi> of the <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi>/<z:chebi fb="11" ids="26333">prostaglandin</z:chebi> endoperoxide receptor in vitro and in vivo and may be of therapeutic use in preventing <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
</text></document>